Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

October 15, 2020October 15, 2020

$7.1M NIH Grant Supports Study of Opioid Alternatives to Manage SCD Pain

News

The National Institutes of Health (NIH) has awarded a $7.1 million grant to University of Illinois Chicago (UIC) researchers to evaluate the effectiveness of two therapeutic strategies as alternatives to opioids in the ... Read more

October 8, 2020October 8, 2020

Rivipansel Granted FDA’s Rare Pediatric Disease Designation for SCD

News

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to GlycoMimetics’ investigational therapy rivipansel (GMI-1070) for the treatment of sickle cell disease (SCD). This designation is ... Read more

June 16, 2020July 9, 2020

Bluebird Bio Presents Data from LentiGlobin Gene Therapy Trial

News

Bluebird Bio’s investigational gene therapy LentiGlobin safely prevents serious vaso-occlusive crises and acute chest syndrome in adolescents and adults with severe sickle cell disease (SCD), according to recent data from ... Read more

February 20, 2020February 20, 2020

Sickle Cell Linked to Faster Kidney Function Decline in African-Americans, Study Shows

News

African-Americans with sickle cell trait and sickle cell disease have a significantly faster decline in kidney function than their unaffected peers with normal hemoglobin, a study suggests. Men, people ... Read more

November 20, 2019September 24, 2020

CTX001 Found to be Safe, Effective in 1st Tested Patient With Severe SCD, Early Data Suggest

News

CTX001 safely and effectively increased the levels of fetal hemoglobin and prevented vaso-occlusive crises in the first severe sickle cell disease (SCD) patient receiving the therapy, according to preliminary data from a ... Read more

July 26, 2018July 26, 2018

Endari Reduces Pain Crises, Hospitalizations in Sickle Cell Patients, Phase 3 Trial Shows

News

Treatment with Endari (L-glutamine) leads to fewer pain crises and hospitalizations in patients with sickle cell disease, according to final results of a Phase 3 clinical trial. These results were ... Read more